Stem cell transplants curb disease activity in active MS
By MS Buddy ·
Summarized from Multiple sclerosis (Houndmills, Basingstoke, England), Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Review · selected people with active relapsing MS and other brain and nerve diseases
Research by Saira Afzal, Jeffrey Cohen and 1 colleague at Neurological Institute in the United States.
Can stem cell transplants control active relapsing MS?
Key Takeaway
Stem cell transplants can provide lasting control of disease activity in selected people with active relapsing MS.

What They Found
The review describes stem cell transplants (treatment using a person's own blood-forming stem cells) as highly effective for selected people with active relapsing MS. Studies and trials found lasting suppression of disease activity linked to inflammation (the body's immune response). Major medical organizations support this option for active MS that has not responded to highly effective MS medicines. The best preparation treatment before a transplant remains unclear. Researchers also remain unsure whether selecting particular stem cells improves results.
Who Should Care and Why
This review focuses mainly on selected people with active relapsing MS. It also discusses transplants for other diseases involving inflammation (the body's immune response) in the brain and nerves. Evidence for those other conditions comes mostly from reports describing small groups of patients. For MS, the review addresses where transplants fit among current treatment choices. It also highlights uncertainty about which people are most likely to benefit.
Important Considerations
This article reviews existing evidence rather than reporting a new trial, and the abstract gives no participant total. You cannot tell from this abstract which preparation treatment or patient selection approach is best. Ongoing trials that randomly assign treatments are expected to strengthen the evidence.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Multiple sclerosis (Houndmills, Basingstoke, England) by . Reproduced from the PubMed record.
Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.
Categories
Explore more research
Related MS research

11/19/2026
A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/19/2026
Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan
Read More
11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read More
11/13/2026
From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
